Molecular Subtyping Enables More Accurate Prognosis and Treatment Selection, According to Research Presented at San Antonio Conference
Genomic tests that determine the molecular subtype of a woman’s breast cancer provide a more precise prognosis and valuable guidance about the best treatment, according to new research led by oncologist Massimo Cristofanilli, MD, director of the Jefferson Breast Care Center at the Kimmel Cancer Center at Jefferson.
Dr. Cristofanilli and colleagues concluded that the genomic tests MammaPrint® and BluePrint® from Agendia help oncologists better select the most effective therapy for individual patients.
At the San Antonio Breast Cancer Symposium (SABCS) the physician-researchers researchers reported that molecular subtyping is superior to traditional, clinical pathology methods at classifying the nature of a woman’s breast cancer and more precisely tailoring each patient’s treatment.
“We found that molecular subtyping is better than traditional methods for determining the exact biological nature of a woman’s cancer and therefore what is the optimal course of treatment that will provide the best outcome for her,” said Dr. Cristofanilli.
“We are now using these genomic tests and molecular subtyping in our everyday clinical practice,” he said. “One advantage of this approach is that we can better identify patients who would most benefit from chemotherapy, and also those who do not need to undergo chemotherapy.”
Chemotherapy risks include immediate side effects, discomfort, and long-term damage. Several studies have concluded that chemotherapy provides no real benefit for many breast cancer patients because of their cancer subtype and low risk of recurrence.
Genomic testing is part of the revolution in personalized medicine. The tests examine the activity of groups of genes within a cancer tumor, to provide a more comprehensive view of the cancer and treatment options. The four subtypes of breast cancer are known as Luminal A, Luminal B, Basal-type and HER2-type.
The MammaPrint test predicts how likely it is that a woman’s breast cancer will recur. BluePrint then identifies the molecular subtype of her cancer and predicts tumor response to targeted therapies before and after surgery.
Breast cancer tumors have traditionally been classified using immunochemistry (IHC) and fluorescent in-situ hybridization (FISH) techniques. Dr. Cristofanilli and colleagues compared the accuracy of IHC and FISH results to MammaPrint and BluePrint, which are part of the Symphony™ panel of genomic tests.
Researchers retrospectively analyzed 325 tumor samples from breast cancer patients whose age, survival and cancer pathology (IHC/FISH) findings were known. Median follow-up on those 325 patients was 10.2 years.
The statistically significant results showed that the genomic tests reclassified 25 percent of patients into different subtypes than the subtypes determined by IHC and FISH. By comparing patients’ outcomes, researchers determined the overall superiority of the genomic tests over IHC and FISH.
MammaPrint and BluePrint more accurately predicted what is known as distant metastasis free survival (DMFS) at 5 years in patients with the various subtypes, including Luminal A-type (best outcome) and triple negative tumors (worse prognosis). BluePrint revealed a different molecular diagnosis than IHC and FISH in all four subtypes of breast cancer:
- 20 out of 208 (10%) diagnosed as luminal-like by IHC/FISH were reclassified as HER2-type (n=7) and as Basal-type (n=13)
- 26 out of 52 (50%) diagnosed as HER2 positive by IHC/FISH were reclassified as Luminal A (n=5), Luminal B (n=13), and Basal-type (n=8)
- 14 out of 65 (22%) diagnosed as triple negative by IHC/FISH were reclassified as Luminal A (n=2), Luminal B (n=5) and Basal-type (n=7)
The American Cancer Society estimates that in the U.S. in 2013, 232,340 women will be diagnosed with and 39,620 women will die of breast cancer.